rasagiline

rasagiline. It is a potent, irreversible, and selective monoamine oxidase B inhibitor used primarily for the treatment of Parkinson's disease. Developed by Teva Pharmaceutical Industries, it is marketed under the brand name Azilect and is indicated both as monotherapy in early disease and as an adjunct to levodopa in more advanced cases. Its mechanism provides symptomatic relief by increasing dopamine levels in the central nervous system.

Medical uses

Rasagiline is approved for the treatment of Parkinson's disease across many regions, including the United States and the European Union. As monotherapy, it is effective in managing early-stage motor symptoms, such as bradykinesia and rigidity. When used as an adjunct therapy, it reduces "off" time in patients experiencing motor fluctuations on levodopa regimens. Clinical trials, such as the TEMPO Study and the ADAGIO study, demonstrated its efficacy and potential for disease modification, though this remains a topic of ongoing research. It is often compared to other MAO-B inhibitors like selegiline.

Adverse effects

Common adverse effects include headache, arthralgia, dyspepsia, and depression. A serious but rare risk is the potential for hypertensive crisis, particularly if dietary tyramine is ingested concurrently, though its selectivity for MAO-B makes this less likely than with non-selective MAO inhibitors. Other notable risks involve interactions with antidepressants like fluoxetine and paroxetine, which may precipitate serotonin syndrome. The U.S. Food and Drug Administration and the European Medicines Agency include warnings regarding these interactions in prescribing information.

Pharmacology

Rasagiline functions as an irreversible inhibitor of the enzyme monoamine oxidase B, predominantly found in the brain. This inhibition prevents the breakdown of dopamine, thereby increasing its availability within the nigrostriatal pathway. It is metabolized primarily in the liver by the cytochrome P450 enzyme CYP1A2 into its major active metabolite, 1-aminoindan. Unlike selegiline, its metabolism does not yield amphetamine derivatives, which may influence its side effect profile. The drug's pharmacokinetics are linear, with steady-state concentrations reached within one week of daily dosing.

History

The development of rasagiline originated from research conducted at Tel Aviv University by Professor Moussa Youdim and colleagues. Teva Pharmaceutical Industries licensed and advanced the compound through clinical development. It received its first regulatory approval from the European Medicines Agency in 2005, followed by clearance from the U.S. Food and Drug Administration in 2006. Key clinical evidence was generated through the pivotal TEMPO Study and the later ADAGIO study, which investigated its potential neuroprotective effects. Its introduction provided a new therapeutic option within the class of MAO-B inhibitors.

Society and culture

Rasagiline is marketed globally under the brand name Azilect by Teva Pharmaceutical Industries. It has been the subject of various direct-to-consumer advertising campaigns, particularly in the United States. The drug's cost and insurance coverage have been points of discussion within healthcare systems. It is listed on the World Health Organization Model List of Essential Medicines, underscoring its recognized therapeutic value. Cultural depictions of Parkinson's disease in media, such as the film Love and Other Drugs, have occasionally brought attention to treatments like rasagiline.